Latest Corgenix Med Corp (CONX) Headlines
Corgenix Medical Corporation posts higher net income of USD178,497 for Q2 fiscal 2014
M2 - Fri Feb 14, 3:06AM CST
Diagnostic test kits company Corgenix Medical Corporation (OTC BB:CONX) reported on Thursday its net income of USD178,497 for second quarter fiscal 2014.
Corgenix Reports Second Quarter Fiscal 2014 Financial Results
Business Wire - Thu Feb 13, 8:15AM CST
Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, today filed its second quarter Form 10-Q and reported its financial results. The report disclosed that the company's revenues and net income increased both for the quarter and year to date. Some of the results highlighted by the report are as follows:
Corgenix to Host Conference Call to Discuss Second Quarter Results
Business Wire - Tue Feb 04, 8:15AM CST
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, February 13, 2014, at 4:00 p.m. EST to discuss the Company's financial and operating performance for its quarter ended December 31, 2013, and the status of the Company's product development and marketing activities.
Corgenix Announces Filing of 510(k) Premarket Notification for FDA Clearance of TxBCardio(TM) Assay
Business Wire - Mon Dec 16, 8:15AM CST
Corgenix Medical Corporation (OTC BB: CONX.OB) announced today that in collaboration with Randox Laboratories, the first premarket notification has been filed with the U.S. Food and Drug Administration pursuant to Section 510(k) of the U.S. Federal Food, Drug and Cosmetic Act for the TxBCardio(TM) immunoturbidimetric (IT) assay.
Corgenix Medical Corp posts lower net income of USD84,000, but higher revenue of USD2.88m in Q1 fiscal 2014
M2 - Tue Dec 03, 7:16AM CST
Diagnostic test kits company Corgenix Medical Corporation (OTCBB:CONX.OB) on Monday reported net income of USD84,000 for the quarter ended 30 September 2013.
Corgenix to Launch New Hepcidin-25 Product at the American Society of Hematology Annual Meeting
Business Wire - Mon Dec 02, 8:15AM CST
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that it will launch the Research-Use-Only (RUO) Hepcidin-25 Chemiluminescent Direct ELISA test kit at the 55th Annual Meeting of the American Society of Hematology (ASH(R)) at the Ernest N. Morial Convention Center in New Orleans. The test kit is based on technology originally developed at Eli Lilly and Company and licensed for further development by Corgenix.
Corgenix Medical Corporation & Zalgen Labs partnership to develop diagnostic test for common virus associated with birth defects
M2 - Tue Nov 19, 4:22AM CST
Diagnostic test kits company Corgenix Medical Corporation (OTC BB:CONX) reported on Monday the launch of a collaboration agreement for "next generation" rapid test kit for the early detection of active cytomegalovirus (CMV) infections.
Corgenix Inks Collaborative Diagnostic Test Development Deal with Zalgen Labs
Business Wire - Mon Nov 18, 8:15AM CST
Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that it has entered into a collaboration agreement with Zalgen Labs, a biotechnology company dedicated to the development of multiple diagnostic testing platforms and immunotherapeutics for high impact neglected infectious diseases.
Corgenix's net income down by 57.6% in Q1 fiscal 2014
M2 - Fri Nov 15, 4:57AM CST
Corgenix Medical Corporation (OTCBB:CONX.OB), a developer and marketer of diagnostic test kits, on Thursday reported net income of USD0.084m, for the first quarter of fiscal 2014, ended 30 September 2013.
Corgenix Reports First Quarter Fiscal 2014 Financial Results
Business Wire - Thu Nov 14, 8:14AM CST
Corgenix Medical Corporation (OTCBB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today filed its fiscal quarter Form 10-Q and reported financial results. The report disclosed that the company achieved record operating results for the quarter ended September 30, 2013.
Corgenix Files Concurrent de novo 510(k) Pre-Market Notification for FDA Clearance of its Hyaluronic Acid (HA) Test Kit
Business Wire - Tue Nov 12, 9:41AM CST
Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, announced today it has filed pre-market notification to the FDA pursuant to Section 510(k) of the U.S. Federal Food, Drug and Cosmetic Act for its Hyaluronic Acid (HA) ELISA Test Kit.
Study: Aspirin Ineffective in 20 Percent of Heart Disease Patients
Business Wire - Thu Nov 07, 8:15AM CST
A major new study conducted in Ireland found that 20 percent of patients with established heart disease were not adequately protected by aspirin. Corgenix Medical Corporation, developers of the AspirinWorks(R) Test for aspirin effect, said the study adds more evidence to the importance of accurately measuring aspirin response by measuring levels of the biomarker thromboxane.
Corgenix Medical Corporation schedules conference call for 14 November 2013 to discuss Q1 results
M2 - Wed Nov 06, 6:05AM CST
Corgenix Medical Corporation (OTC Markets:CONX) stated on Tuesday that it will host a conference call on 14 November 2013 at 16:00 EST.
Corgenix to Host Conference Call to Discuss First Quarter Results
Business Wire - Tue Nov 05, 8:15AM CST
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, November 14, 2013, at 4:00 PM EST to discuss the Company's financial and operating performance for its quarter ended September 30, 2013, and the status of the Company's product development and marketing activities.
Corgenix Medical Corporation enters into diagnostic test development partnership with Health Diagnostic Laboratory
M2 - Tue Oct 29, 8:40AM CDT
Diagnostic test kits company Corgenix Medical Corporation (Other OTC:CONX) reported on Monday the launch of a strategic partnership to advance the development of its clinical Laboratory Developed Test (LDT) with Health Diagnostic Laboratory Inc (HDL Inc).
Corgenix Announces Diagnostic Test Development Partnership with Health Diagnostic Laboratory, Inc.
Business Wire - Mon Oct 28, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced a strategic partnership with Health Diagnostic Laboratory, Inc. (HDL, Inc.) for the development of a clinical Laboratory Developed Test (LDT). The LDT would be based on Corgenix' patented proprietary atherosclerosis biomarker technology for potential use in assessing heart disease risk.
Corgenix to Host Conference Call to Discuss Fiscal 2013 Results
Business Wire - Wed Sep 18, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Monday, September 30, 2013, at 4:00 PM EDT to discuss the Company's financial and operating performance for its fiscal year ended June 30, 2013, and the status of the Company's product development and marketing activities.
Corgenix Medical Corporation renews agreement with Dr Matsuura and retains right to the AtherOx technology
M2 - Wed Sep 11, 9:38AM CDT
Diagnostic kits company Corgenix Medical Corporation (OTCQB:CONX.OB) reported on Tuesday the execution of a new AtherOx License and Cooperation Agreement with Dr Eiji Matsuura of Okayama, Japan.
Corgenix Medical Corporation Announces New AtherOx(R) (Oxidized LDL Technology) License and Cooperation Agreement
Business Wire - Tue Sep 10, 8:15AM CDT
Corgenix Medical Corporation (OTCQB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced signing of a new AtherOx(R) License and Cooperation Agreement with Eiji Matsuura, Ph.D., an individual of Okayama, Japan. Concurrently with the execution of the new agreement, Dr. Matsuura terminated his arbitration demand of June 28, 2013 related to the April 14, 2010 Amended and Restated License Agreement between the parties.
Corgenix Medical Corporation reports new USD1.5m revolving credit facility, with favorable interest rate and greater flexibility
M2 - Thu Sep 05, 6:29AM CDT
Diagnostic test kits company Corgenix Medical Corporation (OTCQB:CONX.OB) revealed on Wednesday the completion of a USD1.5m secured revolving line of credit with Bank of the West.
Corgenix Medical Corporation posts higher net income of USD178,497 for Q2 fiscal 2014
M2 - Fri Feb 14, 3:06AM CST
Diagnostic test kits company Corgenix Medical Corporation (OTC BB:CONX) reported on Thursday its net income of USD178,497 for second quarter fiscal 2014.
Corgenix Reports Second Quarter Fiscal 2014 Financial Results
Business Wire - Thu Feb 13, 8:15AM CST
Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, today filed its second quarter Form 10-Q and reported its financial results. The report disclosed that the company's revenues and net income increased both for the quarter and year to date. Some of the results highlighted by the report are as follows:
Corgenix to Host Conference Call to Discuss Second Quarter Results
Business Wire - Tue Feb 04, 8:15AM CST
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, February 13, 2014, at 4:00 p.m. EST to discuss the Company's financial and operating performance for its quarter ended December 31, 2013, and the status of the Company's product development and marketing activities.
Corgenix Announces Filing of 510(k) Premarket Notification for FDA Clearance of TxBCardio(TM) Assay
Business Wire - Mon Dec 16, 8:15AM CST
Corgenix Medical Corporation (OTC BB: CONX.OB) announced today that in collaboration with Randox Laboratories, the first premarket notification has been filed with the U.S. Food and Drug Administration pursuant to Section 510(k) of the U.S. Federal Food, Drug and Cosmetic Act for the TxBCardio(TM) immunoturbidimetric (IT) assay.
Corgenix Medical Corp posts lower net income of USD84,000, but higher revenue of USD2.88m in Q1 fiscal 2014
M2 - Tue Dec 03, 7:16AM CST
Diagnostic test kits company Corgenix Medical Corporation (OTCBB:CONX.OB) on Monday reported net income of USD84,000 for the quarter ended 30 September 2013.
Corgenix to Launch New Hepcidin-25 Product at the American Society of Hematology Annual Meeting
Business Wire - Mon Dec 02, 8:15AM CST
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that it will launch the Research-Use-Only (RUO) Hepcidin-25 Chemiluminescent Direct ELISA test kit at the 55th Annual Meeting of the American Society of Hematology (ASH(R)) at the Ernest N. Morial Convention Center in New Orleans. The test kit is based on technology originally developed at Eli Lilly and Company and licensed for further development by Corgenix.
Corgenix Medical Corporation & Zalgen Labs partnership to develop diagnostic test for common virus associated with birth defects
M2 - Tue Nov 19, 4:22AM CST
Diagnostic test kits company Corgenix Medical Corporation (OTC BB:CONX) reported on Monday the launch of a collaboration agreement for "next generation" rapid test kit for the early detection of active cytomegalovirus (CMV) infections.
Corgenix Inks Collaborative Diagnostic Test Development Deal with Zalgen Labs
Business Wire - Mon Nov 18, 8:15AM CST
Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that it has entered into a collaboration agreement with Zalgen Labs, a biotechnology company dedicated to the development of multiple diagnostic testing platforms and immunotherapeutics for high impact neglected infectious diseases.
Corgenix's net income down by 57.6% in Q1 fiscal 2014
M2 - Fri Nov 15, 4:57AM CST
Corgenix Medical Corporation (OTCBB:CONX.OB), a developer and marketer of diagnostic test kits, on Thursday reported net income of USD0.084m, for the first quarter of fiscal 2014, ended 30 September 2013.
Corgenix Reports First Quarter Fiscal 2014 Financial Results
Business Wire - Thu Nov 14, 8:14AM CST
Corgenix Medical Corporation (OTCBB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today filed its fiscal quarter Form 10-Q and reported financial results. The report disclosed that the company achieved record operating results for the quarter ended September 30, 2013.
Corgenix Files Concurrent de novo 510(k) Pre-Market Notification for FDA Clearance of its Hyaluronic Acid (HA) Test Kit
Business Wire - Tue Nov 12, 9:41AM CST
Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, announced today it has filed pre-market notification to the FDA pursuant to Section 510(k) of the U.S. Federal Food, Drug and Cosmetic Act for its Hyaluronic Acid (HA) ELISA Test Kit.
Study: Aspirin Ineffective in 20 Percent of Heart Disease Patients
Business Wire - Thu Nov 07, 8:15AM CST
A major new study conducted in Ireland found that 20 percent of patients with established heart disease were not adequately protected by aspirin. Corgenix Medical Corporation, developers of the AspirinWorks(R) Test for aspirin effect, said the study adds more evidence to the importance of accurately measuring aspirin response by measuring levels of the biomarker thromboxane.
Corgenix Medical Corporation schedules conference call for 14 November 2013 to discuss Q1 results
M2 - Wed Nov 06, 6:05AM CST
Corgenix Medical Corporation (OTC Markets:CONX) stated on Tuesday that it will host a conference call on 14 November 2013 at 16:00 EST.
Corgenix to Host Conference Call to Discuss First Quarter Results
Business Wire - Tue Nov 05, 8:15AM CST
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, November 14, 2013, at 4:00 PM EST to discuss the Company's financial and operating performance for its quarter ended September 30, 2013, and the status of the Company's product development and marketing activities.
Corgenix Medical Corporation enters into diagnostic test development partnership with Health Diagnostic Laboratory
M2 - Tue Oct 29, 8:40AM CDT
Diagnostic test kits company Corgenix Medical Corporation (Other OTC:CONX) reported on Monday the launch of a strategic partnership to advance the development of its clinical Laboratory Developed Test (LDT) with Health Diagnostic Laboratory Inc (HDL Inc).
Corgenix Announces Diagnostic Test Development Partnership with Health Diagnostic Laboratory, Inc.
Business Wire - Mon Oct 28, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced a strategic partnership with Health Diagnostic Laboratory, Inc. (HDL, Inc.) for the development of a clinical Laboratory Developed Test (LDT). The LDT would be based on Corgenix' patented proprietary atherosclerosis biomarker technology for potential use in assessing heart disease risk.
Corgenix to Host Conference Call to Discuss Fiscal 2013 Results
Business Wire - Wed Sep 18, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Monday, September 30, 2013, at 4:00 PM EDT to discuss the Company's financial and operating performance for its fiscal year ended June 30, 2013, and the status of the Company's product development and marketing activities.
Corgenix Medical Corporation renews agreement with Dr Matsuura and retains right to the AtherOx technology
M2 - Wed Sep 11, 9:38AM CDT
Diagnostic kits company Corgenix Medical Corporation (OTCQB:CONX.OB) reported on Tuesday the execution of a new AtherOx License and Cooperation Agreement with Dr Eiji Matsuura of Okayama, Japan.
Corgenix Medical Corporation Announces New AtherOx(R) (Oxidized LDL Technology) License and Cooperation Agreement
Business Wire - Tue Sep 10, 8:15AM CDT
Corgenix Medical Corporation (OTCQB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced signing of a new AtherOx(R) License and Cooperation Agreement with Eiji Matsuura, Ph.D., an individual of Okayama, Japan. Concurrently with the execution of the new agreement, Dr. Matsuura terminated his arbitration demand of June 28, 2013 related to the April 14, 2010 Amended and Restated License Agreement between the parties.
Corgenix Medical Corporation reports new USD1.5m revolving credit facility, with favorable interest rate and greater flexibility
M2 - Thu Sep 05, 6:29AM CDT
Diagnostic test kits company Corgenix Medical Corporation (OTCQB:CONX.OB) revealed on Wednesday the completion of a USD1.5m secured revolving line of credit with Bank of the West.
